OBJECTIVE: Structural validity for the Health Assessment Questionnaire-Disability Index (HAQ-DI) has recently been provided for patients with rheumatoid arthritis (RA). The goal of the current study was to examine the structural validity of the HAQ-DI in patients with systemic sclerosis (SSc, scleroderma) and to compare its performance with that in patients with RA. METHODS: The HAQ-DI structural validity was first assessed in a sample of 100 scleroderma patients using confirmatory factor analysis. Second, the similarity of factor structures between SSc patients (n = 291) and RA patients (n = 278) was tested using a multigroup structural validity model to assure that comparison of scores between these two diagnostic groups is appropriate. RESULTS: Results yielded a single-factor HAQ-DI score which favored the current scoring system of the HAQ-DI (model fit was CFI = 0.99 and RMSEA = 0.04). Moreover, even the most stringent model of multigroup structural validity affirmed the similarity between SSc and RA patients on the HAQ-DI (model fit was CFI = 0.99 and RMSEA = 0.04) nor was it different from a model without any demands on group similarity: CFI difference = 0.007; chi(2) = 4.29, df = 26, p=0.99. CONCLUSION: The current results indicate that a single-factor HAQ-DI is appropriate for future clinical trials in scleroderma and, in addition, HAQ-DI scores among patients with SSc and early RA can be compared legitimately with one another.
OBJECTIVE: Structural validity for the Health Assessment Questionnaire-Disability Index (HAQ-DI) has recently been provided for patients with rheumatoid arthritis (RA). The goal of the current study was to examine the structural validity of the HAQ-DI in patients with systemic sclerosis (SSc, scleroderma) and to compare its performance with that in patients with RA. METHODS: The HAQ-DI structural validity was first assessed in a sample of 100 sclerodermapatients using confirmatory factor analysis. Second, the similarity of factor structures between SSc patients (n = 291) and RApatients (n = 278) was tested using a multigroup structural validity model to assure that comparison of scores between these two diagnostic groups is appropriate. RESULTS: Results yielded a single-factor HAQ-DI score which favored the current scoring system of the HAQ-DI (model fit was CFI = 0.99 and RMSEA = 0.04). Moreover, even the most stringent model of multigroup structural validity affirmed the similarity between SSc and RApatients on the HAQ-DI (model fit was CFI = 0.99 and RMSEA = 0.04) nor was it different from a model without any demands on group similarity: CFI difference = 0.007; chi(2) = 4.29, df = 26, p=0.99. CONCLUSION: The current results indicate that a single-factor HAQ-DI is appropriate for future clinical trials in scleroderma and, in addition, HAQ-DI scores among patients with SSc and early RA can be compared legitimately with one another.
Authors: R Westhovens; J C Cole; T Li; M Martin; R Maclean; P Lin; B Blaisdell; G V Wallenstein; R Aranda; Y Sherrer Journal: Rheumatology (Oxford) Date: 2006-03-27 Impact factor: 7.580
Authors: Dinesh Khanna; Philip J Clements; Daniel E Furst; Yun Chon; Robert Elashoff; Michael D Roth; Mildred G Sterz; Joannie Chung; John D FitzGerald; James R Seibold; John Varga; Arthur Theodore; Fredrick M Wigley; Richard M Silver; Virginia D Steen; Maureen D Mayes; M Kari Connolly; Barri J Fessler; Naomi F Rothfield; Kamal Mubarak; Jerry Molitor; Donald P Tashkin Journal: Arthritis Rheum Date: 2005-02
Authors: Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash Journal: Arthritis Rheum Date: 2003-01
Authors: Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays Journal: Qual Life Res Date: 2007-04-03 Impact factor: 4.147
Authors: Sarah D Mills; Rina S Fox; Erin L Merz; Philip J Clements; Suzanne Kafaja; Vanessa L Malcarne; Daniel E Furst; Dinesh Khanna Journal: J Rheumatol Date: 2015-06-01 Impact factor: 4.666
Authors: Maaike M van Groen; Peter M ten Klooster; Erik Taal; Mart A F J van de Laar; Cees A W Glas Journal: Qual Life Res Date: 2010-06-18 Impact factor: 4.147
Authors: Shelley E Condon; Scott C Roesch; Philip J Clements; Daniel E Furst; Michael H Weisman; Vanessa L Malcarne Journal: J Scleroderma Relat Disord Date: 2020-06-22
Authors: Alexandra B Wiese; Veronica J Berrocal; Daniel E Furst; James R Seibold; Peter A Merkel; Maureen D Mayes; Dinesh Khanna Journal: Arthritis Care Res (Hoboken) Date: 2014-11 Impact factor: 4.794
Authors: Matylda Sierakowska; Halina Doroszkiewicz; Justyna Sierakowska; Marzena Olesińska; Agnieszka Grabowska-Jodkowska; Marek Brzosko; Piotr Leszczyński; Katarzyna Pawlak-Buś; Bogdan Batko; Piotr Wiland; Maria Majdan; Małgorzata Bykowska-Sochacka; Wojciech Romanowski; Aleksandra Zon-Giebel; Sławomir Jeka; Mwidimi Ndosi Journal: Qual Life Res Date: 2019-09-03 Impact factor: 4.147